Palisades Goldcorp Ltd is a Canadian resource merchant bank. The company is engaged in investing in resource properties.
相关临床试验
4
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2011
进行中（未招募）
1
25.0%
已完成
2
50.0%
终止
1
25.0%
暂无批准数据
- Palisade Bio appointed Robert Baltera and Jordan Zwick to its Board of Directors, bringing decades of biopharma leadership, strategic transactions, and capital markets expertise. - The appointments come as the company's lead candidate PALI-2108, a once-daily oral PDE4 inhibitor prodrug, advances toward Phase 2 development in ulcerative colitis and Crohn's disease. - PALI-2108 has generated positive clinical data from a Phase 1a trial and two Phase 1b trials, including studies in ulcerative colitis and fibrostenotic Crohn's disease. - Both new directors highlighted PALI-2108's differentiated profile and its potential to address significant unmet needs in inflammatory bowel disease.
- Recent clinical trial developments in Crohn's disease include positive Phase 2a data for Agomab's ontunisertib in fibrostenosing disease and completion of first cohorts for Onco3R's SIK3 inhibitor O3R-5671. - TREMFYA demonstrates durable remission at two years as the first IL-23 inhibitor with fully subcutaneous treatment regimen, while receiving EC approval for ulcerative colitis maintenance therapy. - Major pharmaceutical companies including AbbVie, Takeda, Johnson & Johnson, and Pfizer continue to drive innovation in Crohn's disease therapeutics through extensive clinical trial programs. - Merck expands its tulisokibart development program with Phase 2b trials in three additional immune-mediated inflammatory diseases, highlighting growing therapeutic options.
- Palisade Bio filed to register 8.9 million shares for resale by selling stockholders, including 8.64 million from warrant exercises, with the company receiving no proceeds from the sales. - The company reported improved financials with a 32% decrease in net loss and reduced research and development expenses as it transitions from preclinical to clinical development of PALI-2108. - Despite positive Phase 1 data for PALI-2108 and a 27.5% stock surge, the company faces delisting risk from Nasdaq due to stock price below $1.00 minimum requirement. - Management plans to submit an IND application with the FDA and commence U.S. clinical trials for PALI-2108 in the first half of 2026 for inflammatory bowel disease treatment.
- Palisade Bio has initiated the multiple ascending dose (MAD) cohorts of its Phase Ia/b trial for PALI-2108 in ulcerative colitis after completing single ascending dose (SAD) cohorts. - Preliminary data from the SAD cohorts showed PALI-2108 was well-tolerated across doses from 15mg to 450mg, with no serious adverse events reported. - Pharmacokinetic analysis of PALI-2108 demonstrated its extended and delayed-release characteristics, crucial for targeted drug exposure in the colon. - Topline data from the Phase Ia/b study, which assesses safety, tolerability, and pharmacokinetics in healthy volunteers and UC patients, is expected in H1 2025.
- PALI-2108, a colon-specific PDE4 inhibitor prodrug, effectively reduced colitis symptoms in a DSS mouse model, suggesting potential for ulcerative colitis (UC) treatment. - The preclinical data indicates that PALI-2108 does not exhibit CNS toxicity, a common concern with systemically acting PDE4 inhibitors, enhancing its safety profile. - Palisade Bio is advancing PALI-2108 through a Phase 1a/b study, with topline data expected in the first half of 2025, marking progress in clinical development. - Pharmacokinetic modeling suggests favorable absorption and bioavailability of PALI-2108, supporting its potential for clinical use with twice-daily induction and once-daily maintenance dosing.
- Alto Neuroscience's ALTO-100 failed to meet its primary endpoint in a Phase 2b trial for major depressive disorder (MDD), as measured by the MADRS scale. - The trial enrolled 301 adults with MDD, defined by a memory-based cognitive biomarker, across 34 sites in the U.S. - Despite the setback, Alto Neuroscience plans to analyze the full data set to determine future steps for ALTO-100 in MDD and remains committed to precision medicine in psychiatry. - The company's stock price plummeted following the announcement, but Alto expects its cash position to fund operations into 2027, with other clinical readouts anticipated.
- Palisade Bio is set to initiate a Phase 1 clinical trial for PALI-2108, a PDE4 inhibitor prodrug, targeting moderate to severely active ulcerative colitis (UC). - The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PALI-2108 in healthy volunteers and UC patients. - Palisade Bio is developing precision medicine tests using PDE4B expression to identify patients most likely to respond to PALI-2108, potentially improving treatment outcomes. - A pre-Clinical Trial Application meeting with Health Canada has been completed, and the CTA for the Phase 1 study has been submitted.
- Palisade Bio identifies PDE4B expression as a potential biomarker for patient stratification in ulcerative colitis (UC), with higher expression in colitis patients. - Data shows elevated PDE4B expression in 70% of adult and 90% of pediatric UC patients, suggesting its utility in identifying suitable candidates for targeted therapies. - PALI-2108, an oral, colon-specific PDE4 inhibitor prodrug, is being advanced by Palisade Bio for UC treatment, with Phase 1 trials expected to commence before year-end. - Preclinical studies in a DSS-induced UC mouse model demonstrated that PALI-2108 reduces colon tissue PDE4B expression and inflammatory cytokines, correlating with decreased disease activity.
